Ergoteles’s Summit Therapeutics SMMT Stock Holding History

Ergoteles’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-12,234	Closed	-$21.4K	–	1487
2023 Q1	$21.4K	Buy	+12,234	New	+$33.4K	﹤0.01%	1158
2022 Q3	–	Sell	-100,722	Closed	-$101K	–	1953
2022 Q2	$101K	Buy	+100,722	New	+$141K	﹤0.01%	1504

Other funds holding SMMT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Ergoteles's SMMT Position: Q2 2023 in Review

Ergoteles sold out of Summit Therapeutics (SMMT) in Q2 2023, closing a stake of 12,234 shares — an estimated $21.4K sold.

Ergoteles first reported a position in SMMT in Q2 2022 and held it in 2 quarters. The position peaked at $101K in Q2 2022. 100 funds tracked by Wall St. Rank hold SMMT as of Q2 2023.

Ergoteles reported no remaining Summit Therapeutics position as of Q2 2023 after selling out during the quarter.
Ergoteles sold 12,234 Summit Therapeutics shares in Q2 2023, an estimated $21.4K.
Ergoteles first reported a position in Summit Therapeutics in Q2 2022 and held it in 2 quarters.
Ergoteles's Summit Therapeutics position peaked at $101K in Q2 2022.
100 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.